REBLOZYL
REBLOZYL (luspatercept-aamt) is an erythroid maturation agent indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. It is also used for adults with very low- to intermediate-risk myelodysplastic syndromes (MDS), including those who are erythropoiesis stimulating agent (ESA)-naïve or those with ring sideroblasts who have failed ESA therapy. The medication serves to manage chronic anemia in these populations but is not indicated for use as a substitute for RBC transfusions when immediate correction is required.
How REBLOZYL Works
Luspatercept-aamt is a recombinant fusion protein that binds to specific endogenous TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling. In conditions like beta thalassemia and MDS, this signaling is abnormally elevated, leading to ineffective red blood cell production. By reducing Smad2/3 signaling, the drug promotes erythroid maturation and increases the percentage of late-stage erythroid precursors in the bone marrow. This mechanism enhances erythropoiesis and improves hematology parameters associated with ineffective erythroid development.
Details
- Status
- Prescription
- First Approved
- 2019-11-08
- Routes
- SUBCUTANEOUS
- Dosage Forms
- POWDER
REBLOZYL Approval History
What REBLOZYL Treats
4 indicationsREBLOZYL is approved for 4 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Anemia
- Beta Thalassemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasm
Drugs Similar to REBLOZYL
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REBLOZYL FDA Label Details
ProIndications & Usage
FDA Label (PDF)REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions . • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions . • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblas...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.